Abstract Enteric Septicemia of Catfish (ESC) is a ruinous bacterial disease affecting the U.S. catfish industry. Previous attempts to develop ESC vaccines have failed to achieve industry acceptance, largely attributed to difficulties in delivering the vaccine to immunocompetent fish. Recently, a live attenuated ESC vaccine has been developed, coupled with a mechanized platform designed to accurately deliver measured doses of vaccine with feed. This delivery scheme for vaccine-feed admixture has shown tremendous promise under controlled research settings. This study evaluated the economic effects of on-going commercial-vaccination trials on catfish fingerling operations in Mississippi. Commercial-vaccination trials for both channel and hybrid catfish demonstrated significant improvement in survival, growth, feed consumption, feed conversion and gross yield. At a realistic vaccination cost of $750/ha, the net economic benefits to channel and hybrid catfish fingerling-production phases were $3199 and $6145/ha, respectively. Whole-farm models showed additional profit ranging from $71,758 to $133,887/400-ha on farms that integrate fingerling production to their production strategies due to appropriation of more of the otherwise incumbent fingerling production acreage into foodfish production. Commercial adoption of the oral-vaccination platform would greatly enhance profitability while laying the foundation for development and delivery of polyvalent vaccines against other catfish diseases.

中文翻译：

---

美国鲶鱼产业商业规模的 Edwardsiella ictaluri 疫苗试验的经济评估

摘要 鲶鱼肠道败血症 (ESC) 是一种影响美国鲶鱼产业的毁灭性细菌疾病。以前开发 ESC 疫苗的尝试未能获得行业认可，主要是由于难以将疫苗提供给具有免疫能力的鱼。最近，开发了一种减毒 ESC 活疫苗，并结合了一个机械化平台，该平台旨在通过饲料准确地提供测量剂量的疫苗。这种疫苗-饲料混合物的输送方案在受控研究环境下显示出巨大的前景。本研究评估了正在进行的商业疫苗接种试验对密西西比州鲶鱼鱼种作业的经济影响。河豚和杂交鲶鱼的商业疫苗接种试验表明存活率、生长、饲料消耗、饲料转化率和总产量。以 750 美元/公顷的实际疫苗接种成本计算，渠道和杂交鲶鱼鱼种生产阶段的净经济效益分别为 3199 美元和 6145 美元/公顷。由于将更多现有的鱼种生产面积用于食用鱼生产，因此全农场模式显示，在将鱼种生产与其生产策略相结合的农场中，额外利润从 71,758 美元到 133,887 美元/400 公顷不等。口服疫苗平台的商业应用将大大提高盈利能力，同时为开发和交付针对其他鲶鱼疾病的多价疫苗奠定基础。由于将更多的现有鱼种生产面积用于食用鱼生产，因此全农场模式显示，在将鱼种生产与其生产策略相结合的农场中，额外利润从 71,758 美元到 133,887 美元/400 公顷不等。口服疫苗平台的商业应用将大大提高盈利能力，同时为开发和交付针对其他鲶鱼疾病的多价疫苗奠定基础。由于将更多现有的鱼种生产面积用于食用鱼生产，因此全农场模式显示，在将鱼种生产与其生产策略相结合的农场中，额外利润从 71,758 美元到 133,887 美元/400 公顷不等。口服疫苗平台的商业应用将大大提高盈利能力，同时为开发和交付针对其他鲶鱼疾病的多价疫苗奠定基础。